Actualites therapeutiques en hepato-gastroenterologie

[en] During the last decade, advances in molecular biology and biotechnology allowed, the development of biological treatments aimed at more precise targets. New algorithms in inflammatory bowel diseases, chronic hepatitis C and digestive oncology are examples of the marked progress achieved by these therapies.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Delwaide, Jean ; Université de Liège - ULiège > Gastro-Entérologie-Hépatologie

Polus, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

French

Title :

Actualites therapeutiques en hepato-gastroenterologie

Alternative titles :

[en] Therapeutic Update in Gastroenterology

Publication date :

2007

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

5-6, May-Jun

Pages :

303-9

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 October 2009

Statistics

Number of views

189 (2 by ULiège)

Number of downloads

107 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Rutgeerts P, Feagan B, Lichtendtein G, et al. - Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology, 2004, 126, 402-413.
Rutgeerts P, Sandborn WJ, Feagan, et al. - Inflixilmab induction and maintenance therapy for active ulcerative colitis: the Act-1 and Act-2 studies. N Engl J Med, 2005, 353, 2462-2476.
Colombel JF, Loftus E, Tremaine W, et al. - The safety profile of infliximab in clinical practice in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology, 2004, 126, 19-31.
Schreiber S, Rutgeerts P, Fedorak RN, et al. - A randomized, placebo-controled trial of certolizumab pegol (CDP 870) for treatment of Crohn's disease. Gastroenterology, 2005, 129, 807-818.
Colombel JF, Sandborn WJ, Rutgeerts P, et al. - Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial. Gastroenterology, 2007, 132, 52-65.
N'Kuize M, Delwaide J, Langlet P, et al. - A multicenter Belgian review of patients infected by HCV genotype 4. Hepatology, 2006, 44, 1, 252A.
Delwaide J, Gérard C, Reenaers C, et al. - Hepatitis C virus genotype 5 in southern Belgium : epidemiological characteristics and response to therapy. Dig Dis Sci, 2005, 50, 2348-2351.
Hui C, Yuen M, Sablon E, et al. - Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis, 2003, 187, 1071-1074.
Pawlotsky JM. - Therapy of hepatitis C : from empirism to eradication. Hepatology, 2006, 43, S207-S220.
Folgori A, Capone S, Ruggeri L, et al. - A T-cell vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med, 2006, 12, 190-197.
Cunningham D, Humblet Y, Siena S, et al. - Cetuximab monotherapy and cetuximab plus Irinitecan in Irinitecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351, 337-345.
Peeters M , Van Cutsem E, Siera S, et al. - A phase III multicenter randomized controlled trial of Panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer. ASCO Annual Meeting Proceedings, 2006, 24, abstract CP-1.
Folkman J. - Tumor angiogenesis : therapeutic implications. N Engl J Med, 1971, 285, 1182-1186.
Hicklin DJ, Ellis LM. - Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 2005, 23, 1011-1027.
Hurwitz H, Fehrenbacher L, Novotny W, et al. - Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350, 2335-2342.
Demetri GD, von Mehren M, Blanke CD, et al. - Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347, 472-480.
Van Oosterom A, Judson I, Verwej J, et al. - Safety and efficacy of imatinib (STI-571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet, 2001, 358, 1421-1423.